Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice.
Publication/Presentation Date
11-4-2020
Abstract
Autoimmune diseases such as multiple sclerosis (MS) develop because of failed peripheral immune tolerance for a specific self-antigen (Ag). Numerous approaches for Ag-specific suppression of autoimmune neuroinflammation have been proven effective in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. One such approach is intravenous tolerance induction by injecting a myelin Ag used for triggering EAE. However, the translation of this and similar experimental strategies into therapy for MS has been hampered by uncertainty regarding relevant myelin Ags in MS patients. To address this issue, we developed a therapeutic strategy that relies on oligodendrocyte (Ol)-derived extracellular vesicles (Ol-EVs), which naturally contain multiple myelin Ags. Intravenous Ol-EV injection reduced disease pathophysiology in a myelin Ag-dependent manner, both prophylactically and therapeutically, in several EAE models. The treatment was safe and restored immune tolerance by inducing immunosuppressive monocytes and apoptosis of autoreactive CD4
Volume
12
Issue
568
ISSN
1946-6242
Published In/Presented At
Casella, G., Rasouli, J., Boehm, A., Zhang, W., Xiao, D., Ishikawa, L. L. W., Thome, R., Li, X., Hwang, D., Porazzi, P., Molugu, S., Tang, H. Y., Zhang, G. X., Ciric, B., & Rostami, A. (2020). Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. Science translational medicine, 12(568), eaba0599. https://doi.org/10.1126/scitranslmed.aba0599
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
33148622
Department(s)
Administration and Leadership
Document Type
Article